Complications for procedure to open clogged pulmonary arteries decrease significantly

For chronic thromboembolic pulmonary hypertension, or CTEPH, balloon pulmonary angioplasty is a novel, nonsurgical treatment

10:11 AM

Author | Noah Fromson

doctors in surgery case looking at screen blue scrubs
The review of a pulmonary angiogram during a balloon pulmonary angioplasty procedure. Credit: Chris Hedley

For patients with high blood pressure in their pulmonary arteries caused by chronic blood clots, complications after a minimally invasive balloon angioplasty have decreased substantially over the last decade, a Michigan Medicine-led study finds. 

Researchers examined over 7,500 cases of balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension, an elevated blood pressure in the pulmonary arteries due to persistent blockages known as CTEPH, between 2013 and 2022. The procedure, which is offered for patients who are not candidates for surgery, involves inflating a balloon inside of diseased lung arteries to break up clots and restore blood flow to the lungs.

Results published in JACC: Cardiovascular Interventions reveal that the once feared severe complications that occur during balloon pulmonary angioplasty — lung injury, coughing up blood and death — all dropped in the latter half of the study decade.

From 2013 to 2017, 11.3% of CTEPH patients experienced lung injury after balloon pulmonary angioplasty, compared to 1.4% between 2018 and 2022. During those same time periods, instances of patients coughing up blood dropped from 14.1% to 7.7% and mortality decreased from 2% to 0.8%.

“Over the last decade, it is clear that balloon pulmonary angioplasty has become a more established, safer option for inoperable CTEPH,” said senior author Vikas Aggarwal, MBBS, interventional cardiologist at the University of Michigan Health Frankel Cardiovascular Center. “We believe these decreased complication rates are largely due to refinement in technique, as well as patient selection. We are learning how to do this procedure in a safer manner with increasing experience over time.”

SEE ALSO: A worsening lung disease deemed hopeless, until doctors tried this treatment

The minimally invasive procedure is performed at select centers worldwide, most often done in an inpatient setting with patients monitored for one to three days after. Another Michigan Medicine-led study in 2023 found that balloon pulmonary angioplasty can be safely performed in an outpatient setting utilizing a novel care delivery protocol.

Outside of balloon pulmonary angioplasty, there are few nonsurgical treatments for CTEPH, which can develop in nearly 5% of all patients with acute pulmonary embolism. Some patients will be treated with lifelong anticoagulation and riociguat, the only approved medication to dilate blood vessels in patients with CTEPH.

“As it becomes clearer that balloon pulmonary angioplasty is a safe and effective treatment that can be carried out in both the inpatient and outpatient setting, there is potential for more centers across the country to start CTEPH programs,” said Victor Moles, M.D., co-author and clinical assistant professor of internal medicine-cardiology at U-M Medical School.

Michigan Medicine is contributing to expanding the knowledge and experience of the procedure by offering complimentary, live on-site programs where interested institutions can learn how to successfully implement balloon pulmonary angioplasty.

“These programs have the potential to greatly increase access and quality of care in treatment of CTEPH,” said Aggarwal, who is also a clinical assistant professor of internal medicine-cardiology at U-M Medical School.

Additional authors include Nishant Jain, M.D., Victor Moles, M.D., Prachi P. Agarwal, M.D., Jonathan Haft M.D., Thomas Cascino, M.D., Kenneth Rosenfield, M.D. Brahmajee K. Nallamothu, M.D., Vallerie McLaughlin, M.D. Whitney Townsend , all of University of Michigan, Muhammad Sheikh, M.D., Southern Illinois University School of Medicine, Divyansh Bajaj, M.D.,  Medical College of Wisconsin, Richard Krasuski, M.D., Duke University Medical Center, Eric Secemsky, M.D., Beth Israel Deaconess Medical Center, Saurav Chatterjee, M.D., North Shore-Long Island Jewish Medical Centers and Scott Visovatti, M.D., Ohio State University. 

Papers cited:

“Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies,” JACC: Cardiovascular Interventions. DOI: 0.1016/j.jcin.2023.01.361

“Safe and Effective Balloon Pulmonary Angioplasty in the Outpatient Setting: The Michigan Medicine Experience,” Journal of the Society for Cardiovascular Angiography & Interventions. DOI: 10.1016/j.jscai.2023.100589


More Articles About:

Lungs and Breathing Hypertension and High Blood Pressure Vascular Disease Cardiovascular: Treatment & Surgery Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Three people in a bar watch a television displaying a sports logo and a person smiling. Shelves with bottles and a counter with glasses are visible.
Health Lab

Jalen Hurts’ blood clot diagnosis: doctors answer common questions

After Jalen Hurts’ blood clot diagnosis, Michigan Medicine experts explain clot risks, treatment and returning safely to sports.
A pill bottle is open and pills are placed onto a hand
Health Lab

Could a diabetes medication be the next wonder drug?

Researchers identified how sotagliflozin may reduce heart attack and stroke risk, potentially offering benefits beyond diabetes care
Portrait of Peter Mourani, M.D., Professor and Associate Chair of Research for the Department of Pediatrics and Division Director of Pediatric Critical Care Medicine at Michigan Medicine and U-M Health C.S. Mott Children's Hospital.
News Release

U-M-led consortium to receive up to $52 million in NIH funding to study why viral respiratory infections affect children differently

A Michigan Medicine-led research consortium has secured approval for up to $52 million in federal funding to launch a multicenter study examining why some young children recover fully from viral lower respiratory tract infections while others develop severe illness or lasting problems such as asthma.